These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1969668)

  • 61. Antagonistic effects of isofloxythepin on dopamine D1 and D2 receptors and behaviors in rats.
    Lau YS; Fung YK; Anderson TM
    Gen Pharmacol; 1997 Nov; 29(5):729-36. PubMed ID: 9347318
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Plasma homovanillic acid, plasma anti-D1 and -D2 dopamine-receptor activity, and negative symptoms in chronically mediated schizophrenia.
    Suzuki E; Kanba S; Nibuya M; Koshikawa H; Nakaki T; Yagi G
    Biol Psychiatry; 1992 Feb; 31(4):357-64. PubMed ID: 1348430
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Infra-additivity of combined treatments with selective D1 and D2 receptor antagonists for inhibiting sucrose reinforcement.
    Schneider LH; Watson CA; Gibbs J; Smith GP
    Brain Res; 1991 May; 550(1):122-4. PubMed ID: 1832327
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neuroleptic-induced supersensitivity and brain iron: I. Iron deficiency and neuroleptic-induced dopamine D2 receptor supersensitivity.
    Ben-Shachar D; Youdim MB
    J Neurochem; 1990 Apr; 54(4):1136-41. PubMed ID: 1968955
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Two distinct classes of dopamine receptor mediating actions of antipsychotics: binding and behavioral studies.
    Sokoloff P; Martres MP; Protais P; Costentin J; Schwartz JC
    Adv Biochem Psychopharmacol; 1983; 36():163-73. PubMed ID: 6134435
    [No Abstract]   [Full Text] [Related]  

  • 67. Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat.
    Fletcher GH; Starr MS
    Eur J Pharmacol; 1987 Jun; 138(3):407-11. PubMed ID: 2957221
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment.
    Tarazi FI; Zhang K; Baldessarini RJ
    J Pharmacol Exp Ther; 2001 May; 297(2):711-7. PubMed ID: 11303062
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The mechanism of action of novel antipsychotic drugs.
    Meltzer HY
    Schizophr Bull; 1991; 17(2):263-87. PubMed ID: 1679253
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intact discrimination reversal learning but slowed responding to reward-predictive cues after dopamine D1 and D2 receptor blockade in the nucleus accumbens of rats.
    Calaminus C; Hauber W
    Psychopharmacology (Berl); 2007 Apr; 191(3):551-66. PubMed ID: 17021925
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mesoaccumbens dopamine-opiate interactions in the control over behaviour by a conditioned reinforcer.
    Phillips GD; Robbins TW; Everitt BJ
    Psychopharmacology (Berl); 1994 Mar; 114(2):345-59. PubMed ID: 7838928
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Scopolamine interactions with D1 and D2 antagonists on radial-arm maze performance in rats.
    Levin ED
    Behav Neural Biol; 1988 Sep; 50(2):240-5. PubMed ID: 2906537
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats.
    Glavan G; Sket D; Zivin M
    Mol Pharmacol; 2002 Feb; 61(2):360-8. PubMed ID: 11809861
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.
    Scatton B
    J Pharmacol Exp Ther; 1982 Jan; 220(1):197-202. PubMed ID: 6118430
    [No Abstract]   [Full Text] [Related]  

  • 75. Dopamine D3 receptor: basic and clinical aspects.
    Schwartz JC; Levesque D; Martres MP; Sokoloff P
    Clin Neuropharmacol; 1993 Aug; 16(4):295-314. PubMed ID: 8104095
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Two directions of dopamine D1/D2 receptor interaction in studies of behavioural regulation: a finding generic to four new, selective dopamine D1 receptor antagonists.
    Daly SA; Waddington JL
    Eur J Pharmacol; 1992 Mar; 213(2):251-8. PubMed ID: 1387846
    [TBL] [Abstract][Full Text] [Related]  

  • 77. In vivo binding to dopamine receptors: a correlate of potential antipsychotic activity.
    McQuade RD; Duffy RA; Coffin VL; Barnett A
    Eur J Pharmacol; 1992 Apr; 215(1):29-34. PubMed ID: 1355442
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neuroleptic drugs and the sigma receptor.
    Hoffman DW
    Am J Psychiatry; 1990 Aug; 147(8):1093-4. PubMed ID: 1973876
    [No Abstract]   [Full Text] [Related]  

  • 79. Chronic cocaine enhances defensive behaviour in the laboratory mouse: involvement of D2 dopamine receptors.
    Filibeck U; Cabib S; Castellano C; Puglisi-Allegra S
    Psychopharmacology (Berl); 1988; 96(4):437-41. PubMed ID: 2907661
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Different effects on dopamine receptors D1 and D2 following long-term usage of L-dopa].
    Wei D
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Apr; 24(2):104-7, 125. PubMed ID: 1830547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.